



Investment Objective

To achieve consistent and above average capital appreciation over the medium to long-term by investing in companies with market capitalization of not more than RM750 million at the time of acquisition.

Investor Profile

The fund is suitable for investors who are willing to accept higher level of risk in order to obtain higher growth of their capital and have a medium to long term investment horizon.

Fund Manager

UOB Asset Management (Malaysia)

Fund Details


Unit NAV	RM4.2918
Fund Size	RM89.6 million
Inception Date	1 April 2005
Management Fee	1.50% per annum

Top 10 Holdings

Frontken	8.6%
D&O Green Technologies	8.4%
Dufu Technology	7.7%
Pentamaster	7.6%
Formosa Prosonic	6.4%
Kobay Tech	5.9%
Thong Guan	4.3%
Duopharma Biotech	4.2%
PIE Industrial	3.9%
Genetec Technology	3.3%

Data as at 30 November 2021

Cumulative Performance Since Inception as at 30 November 2021




Performance Table as at 30 November 2021

	1 month	3 months	6 months	YTD	1 year	3 years	5 years	Since inception
Fund	-3.9%	1.6%	9.8%	16.3%	17.2%	82.9%	105.1%	803.5%
Benchmark	-4.1%	-4.7%	-3.6%	-5.8%	-2.2%	-4.5%	-2.4%	89.0%

- Benchmark: FTSE Bursa Malaysia Emas Index
- Source: Bloomberg & Gibraltar BSN Life Bhd

Past performance is not indicative of future performance and the performance of the fund is not guaranteed.

Portfolio Composition as at 30 November 2021



Source: UOBAM



Manager's Comment

For November 2021, the Fund's NAV/unit decreased by 3.9%, outperformed the FBM EMAS which decreased by 4.1% mainly due to the Fund's underweight position in the financial sector.

Global equities ended the month in negative territory as market sentiment deteriorated due to expectations of a quicker pace of Fed tapering coupled with the emergence of a new Covid-19 variant dubbed Omicron. The US Fed Chairman, Jerome Powell, commented that the central bankers would be discussing whether to hasten its tapering programme in view of a strong economy while high inflation is expected to last into mid-2022.

The FBM KLCI Index declined 3.1% to close at 1,514 points on the back of negative earnings impact from the one-off prosperity tax announced in the recent Budget and concerns surrounding the Omicron variant. The healthcare sector was among the best performing sector in November driven by news flow on Omicron. Besides that, Malaysia's GDP in 3Q21 came in below expectations at -3.6% QoQ, as the country was under strict mobility curbs in the month of July and August.

Malaysian equities were impacted by market unfriendly measures under Budget 2022 such as the one-off prosperity tax. This was exacerbated by the emergence of Omicron variant. As the country has achieved herd immunity and is rolling out booster inoculations, we believe that the prospects of economy reopening remain intact assuming that existing vaccines are effective against the Omicron variant.

We would adopt a barbell strategy and target to have a balanced exposure in both growth and value/reopening sectors. For growth exposure, we prefer the technology and industrial sector. As for value/reopening, we focus on consumer and commodities.

Disclaimer

This report is for information only and is purely a product summary. Please refer to the product fact sheet available at www.gibraltarbsn.com for further details. This report shall not be reproduced, copied, circulated or forwarded either in part or otherwise to any persons howsoever without the prior written consent of Gibraltar BSN Life Berhad.

The opinions and information contained herein are based on the latest available data which is believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell any securities or financial instruments covered by this report. Gibraltar BSN Life Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Gibraltar BSN Life Berhad and/or its associated persons. Gibraltar BSN Life Berhad and/or its associated persons may from time to time have an interest in the securities or financial instruments mentioned by this report. Past Performance of the Funds mentioned in the Report is not an indication of its future performance. Investors/policy holders should rely on their own evaluation to assess the merits and risks of the investment. In considering to invest in an investment-linked fund, investors/policy holders who are in doubt on the action to be taken should consult a professional adviser. Investors/Policy holders have to take note that investments can fluctuate in value and values may fall as well as rise and an investor/policy holder may not get back the amount invested.